Accelerated Medicines Partnership (AMP)
AMP is a new venture that brings together the Foundation for the National Institutes of Health (FNIH), the National Institute of Health (NIH), 10 bio pharmaceutical companies and several non-profit organizations to work toward a common goal of earlier drug discovery and development for diseases, including rheumatoid arthritis and lupus. As part of this cross-sector partnership, we will be able to share expertise and resources in a way that enables the best informed contributions to science. One critical component of this partnership is that industry partners will make the data and analysis resulting from AMP available to the broader bio-medical community. Learn More.
Arthritis Internet Registry (AIR)
You can help make a difference in the lives of people with arthritis today – and for years to come! Join AIR and the data you provide can help scientists better understand and potentially cure this disease. This registry is run, in-part, by the experts at the National Data Bank for Rheumatic Diseases (NDB), a non-profit research group. There's no obligation to offer any information you don't feel comfortable providing and you can opt out of the research at any time. The Arthritis Internet Registry is brought to you by the Arthritis Foundation, the National Data Bank for Rheumatic Diseases, Researchers at Brigham and Women's Hospital and Harvard Medical School, and Quest Diagnostics. Learn More.
The Biomarkers Consortium
The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics. The consortium is helping create a new era of personalized medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease. Learn More.
The Childhood Arthritis and Rheumatology Research Alliance (CARRA)
The Arthritis Foundation has supported CARRA from the start, providing funding for its development and ongoing funding for its administrative core and support for the CARRA registry. CARRA has created consensus treatment plans to improve and standardize care of pediatric rheumatic diseases. Learn More.
Healthy People 2020
Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For 3 decades, Healthy People has established benchmarks and monitored progress over time in order to: Encourage collaborations across communities and sectors, empower individuals toward making informed health decisions, and measure the impact of prevention activities. Learn More.
The Arthritis Foundation is sponsoring the Sage Bionetworks' (a non-profit research organization working to redefine how complex biological data is gathered, shared and used) Rheumatoid Arthritis Responder DREAM Challenge that is intended to crowdsource human genetics with the ultimate objective of identifying genetic predictors that could improve treatment for those suffering from Rheumatoid Arthritis (RA). Learn More.